Skip to main content
Signal8

Ocean Biomedical, Inc. (OCEA)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Ocean Biomedical, Inc. logo

Ocean Biomedical, Inc.

OTC:OCEAHealthcare
$0.0001
Mkt Cap$23K
EV-
Float206.24M
O/S232.37M
VOL9K sh
$ Vol$1
RVOL0.12×
Inst Own0.0%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.00010.00010.00010.00019,087
Nov 16, 20260.00020.00020.00020.0002456
Nov 13, 20260.00010.00010.00010.000138,757
Nov 12, 20260.00010.00010.00010.0001300,225
Nov 11, 20260.00010.00010.00000.0000564,823
Nov 10, 20260.00010.00010.00010.000156,283
Nov 9, 20260.00010.00040.00010.000154,033
Nov 6, 20260.00010.00040.00010.00019,611
Nov 5, 20260.00040.00040.00040.00041,000
Nov 4, 20260.00010.00040.00010.000451,752
Nov 3, 20260.00010.00050.00010.00051,739
Nov 2, 20260.00020.00060.00020.00022,994
Oct 30, 20260.00020.00060.00020.000322,181
Oct 29, 20260.00020.00060.00010.0002182,154
Oct 27, 20260.00080.00080.00080.0008166
Oct 23, 20260.00050.00080.00050.000828,313
Oct 20, 20260.00050.00050.00050.0005110
Oct 19, 20260.00000.00050.00000.00053,143
Oct 16, 20260.00060.00060.00010.0006312
Oct 15, 20260.00020.00020.00020.000257,557
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
0.0%
Institutional
(2)
0.0%
Insiderⓘ
(0)
0.0%
5%+ Owners
(0)
100.0%
Unattributed (incl. retail)ⓘ
Institutional0.0%
Unattributed (incl. retail)100.0%
Top Shareholders
Sources: 13F, 13D/13GO/S: 232.4M · as of 15 May 2025 · SEC filings
Insiders & Institutional Holders
About

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation.

The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients.

The company was incorporated in 2019 and is based in Providence, Rhode Island.

Key Metrics
Market Cap$23,237
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.02%

based on 232.37M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateNov 8, 2021
Shares Outstanding232.37M
Authorized Shares
Float206.24M
Float (other source)207.37MSignal8 estimate from ownership filings · from DEF 14A, 2025-02-26
52-Week Range
$0.0000$0.0059
$0.0001(2nd percentile)
Volume
Average Daily Volume73.71K
9.09K today vs 73.71K avg(-88%)

30d Avg

73.71K

60d Avg

60.86K

90d Avg

62.95K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Ocean Biomedical, Inc. (OTC: OCEA) traded at $0.0001 on Nov 17, 2026. 52-week range: $0.0000 to $0.0059. The company is in the Healthcare sector (Biotechnology).